Relmada Therapeutics, Inc. RLMD
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -41.82% | -7.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.87% | 11.64% | |||
| Operating Income | 22.87% | -11.64% | |||
| Income Before Tax | 32.22% | 4.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.22% | 4.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.22% | 4.11% | |||
| EBIT | 22.87% | -11.64% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 47.77% | 32.35% | |||
| Normalized Basic EPS | 47.04% | 23.45% | |||
| EPS Diluted | 47.77% | 32.35% | |||
| Normalized Diluted EPS | 47.04% | 23.45% | |||
| Average Basic Shares Outstanding | 29.77% | 41.74% | |||
| Average Diluted Shares Outstanding | 29.77% | 41.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||